Attending TCT in Boston in a few weeks? Want to get "wicked smart" about treating coronary calcium? Shockwave has a lot in store for you:
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Attending TCT in Boston in a few weeks? Want to get "wicked smart" about treating coronary calcium? Shockwave has a lot in store for you:
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Recognizing Shockwave’s commitment to drive value through clinical excellence and commitment to lower costs, Shockwave was announced a winner of the Supplier Horizon Award from Premier Inc., a leading healthcare improvement and technology company that unites an alliance of more than 4,400 U.S. hospitals and health systems and approximately 225,000 other providers. We're thrilled to be honored by Premier Inc. as a Supplier Horizon winner at the Breakthroughs Conference 2022 as it represents the support provided to Premier members of “exceptional customer service and engagement.”
Shockwave received this award for being a preferred supplier in the healthcare industry and demonstrating “unwavering commitment to delivering top value products and services designed to continually improve patient care.” This award, “recognizes suppliers - with less than three years of Premier tenure in a specific service line - that consistently support our members at the highest levels of partnership, customer service, value creation, clinical excellence, and commitment to lower costs.” Shockwave supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies,” said David A. Hargraves, Senior Vice President, Supply Chain, Premier, “We’re honored to recognize them as a Horizon Award recipient.”
The full list of Premier’s 2022 Supplier Horizon Award winners can be found here.
Topics: IVL Technology, SWAV News
We had an amazing time seeing you all in person at conferences this past quarter. We accomplished a great deal these past three months—from sharing the randomized Disrupt PAD III Study results at SCAI 2022 to launching Shockwave M5+ across the globe. JSCAI also published two articles discussing peripheral IVL for treatment of calcified common femoral artery disease, and the mid-term outcomes from the randomized Disrupt PAD III Trial. Check out the latest in the PulsePoint newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, PulsePoint Newsletter
At Shockwave, we are committed to doing everything we can to narrow the PCI gender inequality gap starting with clinical evidence presented at SCAI 2022 where Coronary IVL demonstrated sustained long term clinical outcomes and excellent safety in both women and men suggesting first line use of Coronary IVL for plaque modification in female patients with calcified lesions.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Female vs. Male Outcomes
Leading female interventionalists came together at SCAI 2022 to discuss what they are most excited about in the interventional space today, share key takeaways from SCAI, and discuss the female focused initiatives that will help bridge the PCI gap in gender disparities going forward. From the JSCAI expert consensus, gender focused clinical evidence highlights at SCAI, and future research to SCAI WIN initiatives, these female leaders covered it all.
Listen to the podcast with Dr. Dawn Abbott, MD, Rhode Island Hospital, Dr. Suzanne Baron, MD, Lahey Hospital and Medical Center, Dr. Alexandra Lansky, MD, Yale University School of Medicine, Yale University and Dr. Nadia Sutton, MD, University of Michigan.
We hope you enjoy the episode and for more information on coronary IVL in women, please visit TimeForAnIntervention.com.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, ChalkTalk Podcast, Female vs. Male Outcomes
With calcium being as hot of a topic as ever in the interventional community, now is the time to invest in research to better understand its impact across patient populations and trends in modification techniques. Shockwave, in partnership with SCAI, is sponsoring a $50,000 grant for research that improves current understanding of calcified lesions. This one-time grant is eligible for SCAI members within 10 years of completing an Interventional Cardiology fellowship. Research must last 1-year and focus within one of the two following areas:
Applicants are encouraged to access the application instructions at this link. Submissions open May 21, 2022 and close August 21, 2022. Awardees will be notified in September 2022.
We hope this grant improves knowledge & understanding of calcified lesions and further informs us of gender, race and age disparities in coronary calcium modification outcomes.
SCAI Early Career Research Grants presented by Dr Sunil Rao at SCAI 2022
Topics: Coronary IVL, IVL Technology, SWAV News, Female vs. Male Outcomes
This year has been “chalk” full of good vibrations at Shockwave! We launched our most efficient IVL catheter yet, the faster-pulsing Shockwave M5+, and its effects have been helping patients with calcified PAD across the globe ever since. Our data also got deeper, with the Disrupt CAD III one-year data published in JSCAI, demonstrating Coronary IVL’s excellent safety and effectiveness outcomes at 30 days out to one year. We heard from physicians like Dr. B. Clay Sizemore on using Coronary IVL in a no-surgical-backup hospital, and Dr. Alexandra Lansky regarding gender disparities in cardiovascular disease. To top it all off, Fast Company recognized Shockwave as one of the World’s Most Innovative Companies for 2022. Check out all of this and more in the latest PulsePoint Newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, PulsePoint Newsletter
In episode #9 of the ChalkTalk podcast, we speak with Alexandra Lansky, MD, FACC, FAHA, FSCAI, FESC, Professor of Medicine in Cardiology, and Director of Yale Cardiovascular Clinical Research Program at Yale University School of Medicine in New Haven, Connecticut, about her recent gender analyses at TCT21 and SCAI22, in which she presented the respective 30-day and 1-year outcomes broken out by women vs men that were enrolled in the Disrupt CAD clinical program.
Dr. Lansky shares the genesis of the analysis - previous research showing that female atherectomy patients have an increased risk for angiographic complications than their male counterparts,[i] and sheds light on what makes coronary IVL unique from a safety perspective. She concludes by discussing the recent publication of SCAI’s “Expert Consensus Statement on Sex-Specific Consideration in Myocardial Revascularization” in JSCAI, which referenced the role of IVL in female patients. The SCAI guidelines concluded, “while additional evidence is needed, these results taken in the context of outcomes with atherectomy devices suggest that IVL may emerge as a first-line therapy for plaque modification of calcified lesions in women specifically.”
We hope you enjoy the episode and for more information on coronary IVL in women, please visit TimeForAnIntervention.com.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, ChalkTalk Podcast, Female vs. Male Outcomes
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Peripheral Conferences, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, Shockwave M5 & Shockwave M5+
After two long years, EuroPCR is finally live again! We can’t wait to meet you in Paris and discuss the latest on IVL.
Topics: Coronary IVL, IVL Technology, Shockwave C2
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
